ACTA1 and Hepatic fibrosis: Groups treated with RBO (0.2 and 0.4 mL/rat) for two weeks post-induction of liver fibrosis showed a significant (p≤0.05) reduction of liver TGF-β1 (5902.0±440.72 and 4905.7±305.98 pg/ml), FAK (11935.1±1079.75 and 11204.8±734.83 pg/mL), and α-SMA (616.4±34.81 and 11204.8±734.83 pg/mL) as compared to control positive group and showing % of reduction in TGF-β (27.5% and 39.74%), FAK (20.55% and 25.41%) and α-SMA (24.04% and 24.86%).